Pelashield™ PainGuard™ vs Restrata® in HS Surgery
NCT: NCT07316192 · RECRUITING
Brief Summary
Hidradenitis Suppurativa (HS) is a long-lasting skin condition that causes painful lumps and infections. In severe cases, patients need surgery to remove the affected skin. After surgery, a wound dressing called a wound matrix is placed over the area to help the skin heal. This study will compare two different wound matrices: Restrata®, which is the current standard treatment. Pelashield™ PainGuard™, a newer dressing that contains silver to reduce bacteria and lidocaine to help with pain. The goal of this research is to find out if Pelashield™ PainGuard™ helps patients heal better after surgery than Restrata®. We will look at: How quickly healthy granulation tissue (new healing tissue) forms How soon the wound is ready for the second surgery to apply a skin graft How often infections happen after surgery How much narcotic (opioid) pain medication patients need after surgery Patients who receive Pelashield™ PainGuard™ will be enrolled in the study going forward (prospective group). Patients who previously had surgery with Restrata® will be included through a review of their medical records (retrospective group). No additional procedures will be done outside of standard surgical care.
Frequently Asked Questions
What is Pelashield™ PainGuard™ vs Restrata® in HS Surgery?
Pelashield™ PainGuard™ vs Restrata® in HS Surgery is a clinical trial registered under NCT07316192. Current status: RECRUITING.
What is the status of NCT07316192?
The current status of NCT07316192 (Pelashield™ PainGuard™ vs Restrata® in HS Surgery) is: RECRUITING.
When did Pelashield™ PainGuard™ vs Restrata® in HS Surgery start?
Pelashield™ PainGuard™ vs Restrata® in HS Surgery started on 2025-12-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.